A Randomised, Placebo-controlled, Parallel Group Single Dose Study of GW856553 in Patients With Active RA to Investigate the C-Reactive Protein (CRP) Dose Response Relationship.
Phase of Trial: Phase II
Latest Information Update: 31 May 2012
At a glance
- Drugs Losmapimod (Primary)
- Indications Rheumatoid arthritis
- Focus Pharmacodynamics
- 31 Aug 2018 Biomarkers information updated
- 13 Jan 2012 Actual patient number changed from 48 to 51 according to ClinicalTrials.gov.
- 13 Jan 2012 Actual end date ( Nov 2006) added as reported by ClinicalTrials.gov.